PCSK9 Inhibitors and Real-World Evidence

When to Consider Nonstatin Therapy

Nonstatin Recommendations From Treatment Guidelines

Beyond Statins – AHA/ACC 2018 Lipid Updates

PCSK9 Inhibitors FDA Indications

PCSK9 Inhibitors Dosing and Administration

FOURIER Outcomes Trial Evolocumab

FOURIER Efficacy Outcomes

FOURIER Safety

FOURIER Total Primary Endpoint Events

ODYSSEY Outcomes Study Alirocumab

Alirocumab ODYSSEY Outcomes Trial Results

OSLER-1 Trial

High-Risk Groups for Future ASCVD Events 2018 ACC/AHA Cholesterol Guidelines

FOURIER Trial PAD Subgroup Analysis

Who Will Benefit Most From "Lowest Is Best" Strategy?

Statin-Associated Muscle Symptoms vs Statin Intolerance

Identify Patients With Statin Intolerance

Statins and Glucose Homeostasis Perception vs Evidence

Improving PCSK9 Inhibitor Approval Rates

Navigating the Prior Authorization Process With the Patient

Navigating the Prior Authorization Process Clinical Pearls

Clinical Tips for Therapeutic Management of PCSK9 Inhibitors

Conclusion

Abbreviations

Abbreviations (cont)